Oncology
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics today announced the closing of its successful £40.5 million ($51.4 million) Series A financing. 27 February 2024
Biotechnology
Last week saw UK pharma major AstraZeneca announce that the US Food and Drug Administration (FDA) has accept its biological license application (BLA) for datopotamab deruxtecan for the treatment of lung cancer and also release positive Phase III results for Tagrisso in lung cancer. The FDA also granted approval for US biotech Iovance’s Amtagvi as a treatment for advanced melanoma, and slapped a clinical trial hold on US drug developer RAPT Therapeutics’ study of zelnecirnon in atopic dermatitis. Also of note, Rigel Pharmaceuticals entered into a deal to acquire US rights to cancer drug Gavreto that were recently handed back to Blueprint Medicines by Swiss pharma giant Roche. 25 February 2024
Biotechnology
On Friday, the US Food and Drug Administration (FDA) announced its final decision to withdraw the marketing authorization of Swedish biotech Oncopeptides’ Pepaxto (melphalan flufenamide). 24 February 2024
Biotechnology
Sino-American healthcare-focused venture capital firm ORI Capital has announced the final close of its second fund. 23 February 2024
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines and one biosimilar for approval at its February 2024 meeting. 23 February 2024
Biotechnology
Japan’s largest drugmaker Takeda decided to discontinue the development programs of its four oncology assets - Phase III asset modakafusp alfa (TAK-573) and three Phase I chimeric antigen receptor (CAR-T) assets: TAK-102, TAK-103 and TAK-940 - as part of a plan to align its focus on advancing allogeneic cell therapies. 23 February 2024
Biotechnology
US pharma major AbbVie revealed yesterday that it has linked up with San Diago, USA-based start-up Tentarix Biotherapeutics on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. 23 February 2024
Biotechnology
Privately-held immuno-oncology company Immune-Onc Therapeutics has announced a Phase Ib/II trial collaboration with Swiss pharma giant Roche. 22 February 2024
Biotechnology
US biotech Rigel Pharmaceuticals today announced that it has entered into a definitive agreement to acquire the US rights to cancer drug Gavreto (pralsetinib) from Blueprint Medicines 22 February 2024
Pharmaceutical
Italian pharma major Recordati saw its shares dip 1.5% to 51.30 euros today, despite releasing a strong set of financial results for full year 2023. 22 February 2024
Biotechnology
US pharma major Bristol Myers Squibb has announced the investment of $400 million into a company facility in Dublin, Ireland. 22 February 2024
Biotechnology
As sales for Daiichi Sankyo and AstraZeneca’s HER2+-targeting antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) continue to skyrocket, the companies are poised for yet another anticipated ADC blockbuster with DS-1062, or datopotamab deruxtecan. 22 February 2024
Biosimilars
South Korean biosimilars company Samsung Bioepis today announced that two new study results for SB17, a proposed biosimilar to Stelara (ustekinumab), marketed by Johnson & Johnson, will be presented at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) being held from February 21 to 24 in Stockholm, Sweden. 22 February 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) submitted by US biotech Regeneron. 21 February 2024
Pharmaceutical
India's pharma landscape has undergone a significant shift towards collaboration and partnership between global big pharma and domestic firms in recent years to drive innovation and expand market reach, according to GlobalData. 21 February 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Tecvayli (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory multiple myeloma (RRMM) patients who have achieved and maintained a complete response or better for a minimum of six months. 21 February 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental new drug application (sNDA) submitted by pharma major Bristol Myers Squibb for Krazati (adagrasib) in combination with cetuximab. 21 February 2024
Biotechnology
RAPT Therapeutics revealed that the US Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company’s Phase IIb trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase IIa trial in asthma. 20 February 2024
Biotechnology
Anglo-Swedish pharma major AstraZeneca has presented positive high-level results from the LAURA Phase III trial of Tagrisso (osimertinib), the company’s best-selling drug. 20 February 2024
Biotechnology
The prevalence of colorectal cancer (CRC) is surging across the eight major markets (8MM: the USA, France, Germany, Italy, Spain, UK, Japan and China) due to an aging population and increased mutation testing. 20 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze